Amal Paul

Combinatorial Treatment Strategy of 177Lu-PSMA-617 and Docetaxel Chemotherapy in Highly PSMA- and FDG-Avid (Pro-PET Score 3) Metastatic Castration-Resistant Prostate Cancer While Considering Pre-taxane PRLT

Abstract 177Lu-PSMA-617 targeted radioligand therapy (RLT) received U.S. Food and Drug Administration approval in 2022 for metastatic castration-resistant prostate cancer (mCRPC) patients progressing after androgen receptor pathway inhibitors and taxane chemotherapy. Despite its...